Stifel raises Boston Scientific stock target to $120, keeps buy rating

On Monday, Stifel analysts increased their price target on Boston Scientific Corporation (NYSE:BSX) shares from $115.00 to $120.00, while reiterating a Buy rating for the medical device company. The adjustment follows recent meetings that left analysts with a positive outlook on the company’s future financial performance. According to InvestingPro data, the stock is trading near its 52-week high of $107.17, with 19 analysts recently revising their earnings expectations upward.

Stifel’s analyst Rick Wise (LON:WISEa) expressed confidence in Boston Scientific’s initial guidance for the year 2025, describing it as "prudently conservative." He highlighted that the company appears to be in a strong position to capitalize on significant operating leverage opportunities as the year progresses. The company’s strong market position is reflected in its impressive 60.69% return over the past year and robust revenue growth of 17.61%.

CFO Daniel Brennan’s remarks were also a key point of reference for the analysts. Brennan pointed out that the company’s Electrophysiology and Watchman divisions, known for their high growth, could lead to positive top-line estimate revisions. Such revisions are anticipated to contribute to even greater operating leverage for Boston Scientific. With a market capitalization of $155.12 billion and a GREAT Financial Health Score from InvestingPro, the company demonstrates strong fundamentals. Discover 20+ additional exclusive insights and detailed analysis in the Pro Research Report, available with an InvestingPro subscription.

The company’s focus on these high-growth areas is expected to bolster its financial standing, providing a solid foundation for the increased price target. Boston Scientific’s strategic positioning and potential for enhanced profitability were central to Stifel’s optimistic assessment.

The updated price target of $120.00 represents a notable increase from the previous target of $115.00, reflecting Stifel’s belief in Boston Scientific’s capacity to outperform in the market. With the maintained Buy rating, the firm continues to endorse the stock as a strong investment option.

In other recent news, Boston Scientific Corporation has received attention from several financial firms following its robust fourth-quarter performance in 2024 and strong outlook for 2025. RBC Capital Markets, Truist Securities, Mizuho (NYSE:MFG) Securities, and Canaccord Genuity have all raised their price targets for the company, while maintaining positive ratings on the shares. Needham, meanwhile, has maintained its Hold rating on the stock.

Boston Scientific reported a 20% year-over-year organic growth and a 27% year-over-year EPS growth in the fourth quarter. The company’s strong performance was driven by factors such as the adoption of PFA technology, growth of the WATCHMAN device, and success in its Urology division. Looking ahead, Boston Scientific has provided a strong initial guide for 2025, forecasting 11% year-over-year organic growth at the midpoint, surpassing consensus expectations.

Analysts at these firms believe that Boston Scientific’s future growth will be driven by solid execution, an innovative product portfolio, and robust end-markets. RBC Capital Markets, Truist Securities, and Mizuho Securities all anticipate the company to outperform estimates and raise forecasts throughout 2025. Canaccord Genuity, despite noting an expected slowdown in growth, still sees the company as a strong player in the market.

These are recent developments that investors should consider when evaluating Boston Scientific. It’s important to note that these are the views of the financial firms and not of this news outlet. As always, investors are encouraged to do their own research before making any investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.